Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A randomized, double-blind, placebo-controlled phase II prevention trial evaluating CP101 in 198 adults with Clostridioides difficile infection (CDI) (recurrent)
Primary outcome measures:
Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication, Safety
Conclusion:
CP101 demonstrated greater effectiveness than a placebo in reducing recurrent CDI, while maintaining a safety profile similar to that of the placebo.
…